Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer

▤ Summary

Arcus Biosciences entered a clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate casdatifan in combination with pumitamig for advanced kidney cancer. The agreement adds two new arms to the BMS-sponsored ROSETTA RCC-208 Phase 1/2 trial. Arcus will supply casdatifan while each company keeps its own development and commercial rights to its assets. The move supports Arcus’s broader strategy to build casdatifan into a backbone therapy across multiple renal cell carcinoma treatment settings.

▦ Linked Companies